October 10, 2017
Clinical Data Demonstrate Favorable Safety, Tolerability and Pharmacokinetics Additional Nonclinical Data Show APX001 is Effective Against a Broad Range of Pathogenic Fungi, Including Deadly Candida auris SAN DIEGO – October 9, 2017 – Amplyx Pharmaceuticals, a company developing novel antimicrobial agents for life-threatening fungal infections, today announced that it presented results from two Phase 1 studies of APX001,...


DNA analysis of 442 Viking skeletons rewrites the story of Viking culture
16. September 2020
Hope that a brain injection could cure type 2 diabetes
7. September 2020
Maude has become the stereotypical migraine patient – but it’s not quite the true picture
31. July 2020


Lundbeckfonden Ventures

Lundbeckfonden Emerge